Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies.
Lu H, Molony RD, Chen D, Jang S, Wolf B, Ewert S, Flaherty M, Xu F, Isim S, Shim Y, Dornelas C, Balke N, Leber XC, Scharenberg M, Koelln J, Choi E, Ward R, Johnson J, Calzascia T, Isnardi I, Williams JA, Lindenbergh PL, van de Donk NWCJ, Mutis T, Huet H, Lees E, Meyer MJ.
Lu H, et al. Among authors: isnardi i.
Mol Cancer Ther. 2020 Oct;19(10):2089-2104. doi: 10.1158/1535-7163.MCT-19-0003. Epub 2020 Aug 26.
Mol Cancer Ther. 2020.
PMID: 32847974